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ABSTRACT
Objective: To systematically review whether the
provision of information on cardiovascular disease
(CVD) risk to healthcare professionals and patients
impacts their decision-making, behaviour and
ultimately patient health.
Design: A systematic review.
Data sources: An electronic literature search of
MEDLINE and PubMed from 01/01/2004 to 01/06/
2013 with no language restriction and manual
screening of reference lists of systematic reviews on
similar topics and all included papers.
Eligibility criteria for selecting studies: (1)
Primary research published in a peer-reviewed journal;
(2) inclusion of participants with no history of CVD; (3)
intervention strategy consisted of provision of a CVD
risk model estimate to either professionals or patients;
and (4) the only difference between the intervention
group and control group (or the only intervention in
the case of before-after studies) was the provision of a
CVD risk model estimate.
Results: After duplicates were removed, the initial
electronic search identified 9671 papers. We screened
196 papers at title and abstract level and included 17
studies. The heterogeneity of the studies limited the
analysis, but together they showed that provision of
risk information to patients improved the accuracy of
risk perception without decreasing quality of life or
increasing anxiety, but had little effect on lifestyle.
Providing risk information to physicians increased
prescribing of lipid-lowering and blood pressure
medication, with greatest effects in those with CVD
risk >20% (relative risk for change in prescribing
2.13 (1.02 to 4.63) and 2.38 (1.11 to 5.10)
respectively). Overall, there was a trend towards
reductions in cholesterol and blood pressure and a
statistically significant reduction in modelled CVD risk
(−0.39% (−0.71 to −0.07)) after, on average,
12 months.
Conclusions: There seems evidence that providing
CVD risk model estimates to professionals and patients
improves perceived CVD risk and medical prescribing,
with little evidence of harm on psychological well-
being.
BACKGROUND
Even though there have been advances in
diagnosis, treatment and prevention of car-
diovascular disease (CVD) in recent decades,
CVD still remains the single largest cause of
death worldwide.1 In 2011, 3 in every 10
deaths were caused by CVD,2 and it is esti-
mated that by 2030, 23.3 million people will
die annually due to CVD.3 This has led to
increasing focus on affordable effective pre-
ventive strategies. These include collective
approaches targeting the wider underlying
determinants of CVD in an attempt to shift
the entire population distribution of CVD
risk factors, and approaches that focus on
identiﬁcation of individuals at high risk. An
integral part of the latter approach is the use
of CVD prognostic models or risk scores,
such as the Framingham risk score,4 QRISK,5
ASSIGN,6 SCORE,7 PROCAM8 and
Reynolds9 which share a core set of
Strengths and limitations of this study
▪ This systematic review is the first to address the
impact of provision of cardiovascular disease
risk model estimates on patients’ or physicians’
behaviour or health outcomes.
▪ The use of broad inclusion criteria and the sys-
tematic search of multiple databases allowed us
to include studies in which assessment of the
impact of provision of a risk score alone was not
the primary outcome.
▪ Despite this, the small number and heterogeneity
of included studies limit the strength of conclu-
sions that can be made. Most report only short-
term changes and those that address behaviour
change use mostly self-reported measures and
are underpowered to detect small changes that
may be clinically important at the population
level.
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established risk factors (age, sex, smoking, blood pres-
sure and total cholesterol) among other risk factors (eg,
Townsend score, family history). These scores enable
estimation of an individual’s risk of developing CVD,
and so have the potential to help physicians with deci-
sions regarding initiation, type and intensity of treat-
ment (eg, cholesterol-lowering treatment and blood
pressure management), to facilitate an informed discus-
sion between physician and patient regarding lifestyle
changes and pharmacological treatment, to improve risk
perception of both physicians and patients, and to
motivate individuals to improve their health-related
behaviours, with the ultimate goal to prevent CVD
events. They also provide an opportunity to prioritise
individuals with the highest CVD risk and so allocate
resources efﬁciently.
Such risk models have been incorporated into many
major clinical guidelines for routine practice10–14 and
the UK National Health Service (NHS) Health Checks
programme which aims to assess CVD risk for all those
aged 40–74 years without pre-existing CVD. Despite this
strong advocacy of the use of such CVD risk models,
relatively little is known about the beneﬁts and harms of
provision of CVD risk model estimates to patients, and
whether their use by physicians actually translates into
improved behavioural and clinical outcomes. Previous
groups have reviewed randomised clinical trials of the
effectiveness of healthcare professionals using a CVD
risk model or score to aid primary prevention,15 the
effectiveness of the use of CVD risk model when com-
bined with lifestyle interventions in the prevention of
CVD,16 the effects of providing individuals with global
CVD risk information with or without tailored interven-
tions,17 and the effects of providing CVD risk model esti-
mates on physician knowledge of global CHD risk.18
These systematic reviews all included studies in which
the provision of a risk model estimate was part of a
multifactorial intervention. To our knowledge, no recent
systematic review has comprehensively addressed the spe-
ciﬁc impact of provision of a CVD risk model estimate to
either practitioners or patients.
The purpose of this review was, therefore, to assess
whether provision of a CVD risk model estimate to
either patients or practitioners, as opposed to other sim-
ultaneous or subsequent interventions, such as lifestyle
advice or exercise programmes, impacts patient or prac-
titioner behaviour or health outcomes.
METHODS
We performed a systematic literature review following an
a priori established study protocol (available on
request). Reporting was according to the PRISMA
statement.19
Search strategy
As part of a larger systematic review on CVD risk scores,
we performed an electronic literature search of
MEDLINE and PubMed from 01/01/2004 to 01/06/
2013 with no language restriction. The search strategy is
described in full in online supplementary appendix 1.
Brieﬂy, it included terms for CVD, coronary heart
disease, hypertension, hyperlipidaemia, stroke or cere-
brovascular disease in combination with terms for risk
assessment, prediction, score or decision support, and
named risk scores. We also reviewed the reference lists
of systematic reviews on this topic15–18 for studies pub-
lished prior to 2004 and manually screened the refer-
ence lists of all included papers.
Study selection
We included studies that met the following criteria: (1)
primary (randomised and non-randomised) studies pub-
lished in a peer-reviewed journal; (2) inclusion of parti-
cipants with no history of CVD; (3) intervention strategy
consisted of provision of a CVD risk model estimate to
either physicians or patients (ie, not just providing a
means by which physicians or patients could calculate
CVD risk score); and (4) the only difference between
the intervention group and control group (or the only
intervention in the case of before-after studies) was the
provision of a CVD risk model estimate. Observational
and qualitative studies, studies calculating CVD scores
for the secondary prevention of CVD or including both
primary and secondary prevention where it was not pos-
sible to separate out the primary prevention group, and
conference abstracts, editorials, commentaries, letters
and reviews were excluded.
We selected studies in a three-stage process. In the
ﬁrst stage, titles of all studies identiﬁed from the elec-
tronic search were screened in duplicate by six reviewers
involved in a large systematic review on CVD risk predic-
tion led by ES and KGMM to identify all studies that
described the application of a risk model into clinical
practice or focused on risk-based management. In the
second stage, this process was repeated with seven
reviewers based on abstract. In the third stage, we com-
bined those studies identiﬁed from stage 2 with studies
from systematic reviews on similar topics,15–18 and two
researchers ( JU-S+SG/BS) independently screened the
titles and abstracts against the inclusion and exclusion
criteria. For studies where a deﬁnite decision to reject
could not be made based on title and abstract alone, we
obtained the full paper for detailed assessment. Two
reviewers ( JU-S and BS) then independently assessed
the full-text articles for the possibility of inclusion in the
review. We excluded papers identiﬁed by both research-
ers as not meeting the inclusion criteria. Any disagree-
ments were resolved by discussion, and a ﬁnal decision
was made at consensus meetings by JU-S, BS and SG.
Data extraction
JU-S and BS independently extracted data from all
studies included in the review using a standardised data
extraction form to reduce bias. The data extracted
included: (1) study characteristics (research question,
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risk model or score used, study design, study setting,
intervention, duration of follow-up, outcomes mea-
sured); (2) selection of participants (inclusion criteria,
method of recruitment/randomisation); (3) participant
characteristics (sample size, age, gender, comorbidity,
level of CVD risk); and (4) measured outcome(s).
Reviewers were not blinded to publication details. We
requested additional unpublished data from the authors
of papers in which it was mentioned that additional data
were available or additional data were required to meet
the inclusion criteria or for clariﬁcation of results.
Quality assessment
JU-S and BS conducted quality assessment at the same
time as data extraction. Since our review included
studies with different designs, we used a checklist based
on the Critical Appraisal Skills Programme guidelines
for cohort studies and randomised controlled trials
(RCTs; available from http://www.casp-uk.net/#!
casp-tools-checklists/c18f8) as an initial framework and
then classiﬁed each study as high, medium or low
quality. No studies were excluded based on quality assess-
ment alone.
Data synthesis and statistical analysis
For analysis, we grouped the measured outcomes into
those relating to risk perception, changes in
health-related behaviour, intermediate outcomes (eg,
blood pressure, cholesterol levels), modelled cardiovas-
cular risk, medication prescribing, anxiety and psycho-
logical well-being, and contact with healthcare
professionals after provision of risk information. For
data on continuous outcomes, where possible, we
expressed results as the difference in the mean change
between groups. Where standardised mean changes
were presented in the studies, we used the SD of the
control group to convert data to non-standardised
changes. Where this was not possible, we presented the
results as mean±SD. For data on binary variables, such as
a change in prescribing or meeting targets, we presented
data as ORs or relative risk and 95% CIs. Where possible
we combined data from different studies using random
effects meta-analysis, but due to variations in study
design and reporting, we were only able to do this for a
small number of outcomes. We analysed all data accord-
ing to the different outcomes and the recipient of the
CVD risk score (physician or patient). For outcomes
with data from three or more studies, we assessed the
heterogeneity between studies using the I2 statistic. We
did not perform formal tests of heterogeneity for out-
comes with data from less than three studies. All analyses
were conducted using statistical software package
STATA/SE V.12. Signiﬁcance was set at p<0.05.
RESULTS
After duplicates were removed, the initial electronic
search identiﬁed 9671 papers (ﬁgure 1). One hundred
and ﬁfty-nine of these were identiﬁed as possible inclu-
sion papers during stage 1 and 2 of the screening. When
the papers from existing systematic reviews were added
to this number, we screened 196 papers at title and
abstract level against the inclusion criteria. We excluded
162 and a further 17 after full-text assessment. The most
common reasons for exclusion were that we were unable
to isolate data on primary prevention or the effect of
giving risk information alone (ﬁgure 1). The analysis is,
therefore, based on 17 studies.20–36
A summary of the characteristics of those 17 studies is
shown in table 1. They showed considerable heterogen-
eity in terms of size, setting, risk score used, duration of
follow-up and outcomes measured. Seven (2 RCTs and 5
before-and-after studies) measured changes in under-
standing or risk, risk perception, psychological well-
being or anxiety with 10 (9 RCTs and 1 before-and-after
study) reporting changes in risk factors, prescribing or
calculated risk. Eleven provided risk information to
patients alone, three to physicians and three to both
patients and physicians. Study quality assessment is sum-
marised in table 2. Overall, it was variable with only one
study being judged as high quality. All nine RCTs report-
ing changes in risk factors, prescribing or calculated risk
were judged as medium or high quality. The effect sizes
between the different studies are, therefore, more likely
to reﬂect between-study heterogeneity for a number of
study characteristics, in particular differences in the
patient populations and delivery of risk information,
than overall quality of the studies.
Table 3 shows additional details about the participants
in each of the studies, including the inclusion criteria,
methods of recruitment and randomisation, and the
baseline CVD risk of participants. Of the nine RCTs
reporting changes in risk factors, prescribing or calcu-
lated risk, ﬁve included only high-risk patients (CVD risk
estimate ≥20%) or those with uncontrolled hyperten-
sion or untreated hyperlipidaemia.28 29 33–35 The other
four25 31 32 36 included both high-risk and low-risk parti-
cipants, with the proportion of each well balanced
between the intervention and control groups.
Risk perception
Two before-and-after studies reported the immediate
effects of receiving risk information. In one, patients
tended to initially overestimate their risk and giving risk
information resulted in a signiﬁcant reduction in per-
ceived risk (eg, mean perceived 10-year risk of CVD fell
from 48% to 20%, n=95, p<0.001).20 The other reported
a signiﬁcant increase in the proportion with accurate
risk perception from 34% to 74% (p<0.0001) following
risk information mostly due to a reduction in the rate of
underestimation (60% to 18% (p<0.0001)), while the
rate of overestimation was low and did not change (7%
to 8%; p=0.82; n=146).26 However, Price et al showed in
their RCT that the risk perception after 4 weeks did not
differ between those who received the risk estimate only
(mean 33.7, SD 18.9) and those who did not (mean
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34.8, SD 19.6; p=0.87). Similar pattern of results were
present when the comparison was made between those
who received risk estimate + lifestyle advice (mean 35.6,
SD 18.6) and those who received lifestyle advice only
(mean 41.8, SD 20.7, p=0.14).
Three studies also reported changes in risk perception
at different time intervals after receipt of risk informa-
tion. In two, patients tended to initially overestimate
their risk and giving risk information resulted in a
sustained signiﬁcant reduction in perceived risk after
2–4 weeks (mean 18% from 32%, n=37, p<0.00 001)27
and 6 weeks (eg, mean perceived 10-year risk of CVD
was 26% after 6 weeks compared with 48% prior to risk
information, n=95, p<0.001).20 Asimakopoulou et al20
additionally showed that, controlling for actual risk,
those patients given their 10-year risk reported consist-
ently higher risk estimates than those given 1-year or
5-year risk estimates, while the 1-year and 5-year groups’
estimates were not signiﬁcantly different from each
other. The third study reported change in perceived risk
7–12 weeks after provision of risk information in one of
four formats (CDC, RISKO, Arizona Heart Institute or
Medical age).21 Forty per cent were initially accurate
(42% underestimating their risk and 18% overestimating
risk) and the majority of respondents did not change
their perceived risk. Those who received feedback that
they were above average risk were more likely to increase
their perceived risk, but all other groups were equally
likely to increase their perceived risk as decrease with
10.4% of those who were told they were below average
risk increasing their perceived risk and 11.9% of those
who were told their risk was higher, decreasing their per-
ceived risk.
Changes in health-related behaviour
Diet
One before-and-after study in general practice30 and
one RCT of factory workers25 included self-reported
changes in diet. The provision of risk information led to
no statistically signiﬁcant changes in reported total fat
intake or unsaturated fat intake at 6 months30 or the per-
centage who increased fruit and vegetable or ﬁbre con-
sumption or reduced fat at 5 months.25 In the latter
study, although not statistically signiﬁcant, the effects of
Figure 1 PRISMA flow diagram.
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Table 1 Characteristics of studies
Author and
date
Study
design Country
Recipient
of risk
information Control group Intervention group
Risk score
provided
Duration
of follow
up
Outcomes
measured
Quality
assessment*
Asimakopoulou
(2008)20
Before-
after
study
England Patient NA Calculation of CVD/
stroke risk followed by
explanation of risk and
discussion about
difference between
patients’ perception and
actual risk
1, 5 or 10 year
UKPDS V.2.0
6 weeks Understanding
and recall of risk
L
Avis (1989)21 RCT USA Patient Baseline interview
and assessment of
perceived risk then
follow-up interview
at 7–12 weeks
Baseline interview,
assessment of
perceived risk and then
health risk appraisal
using one of four risk
instruments and
feedback on risk then
follow-up interview at
7–12 weeks
CDC/HRA;37
The Heart
Test;38
RISKO;39
Determine Your
Medical Age40
7–
12 weeks
Change in
perceived risk
L
Christensen
(1995)22
Before-
after
study
Denmark Patient NA Health examination with
calculation of risk score
and health talk with the
GP
Risk of
coronary artery
disease41
6 months Change in
psychological
well-being
L
Christensen
(2004)23
RCT Denmark Patient Baseline
questionnaire
Baseline questionnaire
plus health screening
with written feedback
from their GPs and
either optional or
planned health
discussions with their
GP (2 intervention
groups)
Risk of
cardiovascular
disease
(modified
from41)
1 and
5 years
Change in
psychological
well-being
L-M
Connelly
(1998)24
Before-
after
study
UK Patient NA Baseline questionnaire
and screening
appointment with
provision of risk score.
Participants at high risk
were offered an
appointment with a
nurse or GP to discuss
in more detail
5-year risk of
CHD based on
Northwick Park
Heart Study42
10 days
and
3 months
Change in
psychological
well-being and
anxiety
M-H
Hanlon
(1995)25
RCT Scotland Patient Health education
(interview backed
Health education plus
feedback on risk score
Dundee risk
score43
5 months Self-reported
change in diet,
M
Continued
Usher-Sm
ith
JA,etal.BM
J
Open
2015;5:e008717.doi:10.1136/bm
jopen-2015-008717
5
O
p
e
n
A
c
c
e
s
s
group.bmj.com
 o
n
 N
ovem
ber 24, 2015 - Published by 
http://bmjopen.bmj.com/
D
ow
nloaded from
 
Table 1 Continued
Author and
date
Study
design Country
Recipient
of risk
information Control group Intervention group
Risk score
provided
Duration
of follow
up
Outcomes
measured
Quality
assessment*
up by written
information) or
health education
and feedback on
serum cholesterol
or health education and
feedback on serum
cholesterol plus
feedback on risk score
alcohol and
smoking
cessation,
reduction in
plasma
cholesterol, and
reduction in risk
score
Hussein
(2008)26
Before-
after
study
USA Patient NA Provision of 5-year CVD
risk estimate in
interview lasting
approximately 5 min
5-year
Framingham
risk
Immediate Accuracy of risk
perception
M
Paterson
(2002)27
Before-
after
study
Canada Patient NA A consultation lasting
approximately 18 min
with a GP working
through a workbook
covering CHD and the
concepts of risk and the
patient’s absolute and
relative risk
10-year risk of
a coronary
event based on
Framingham
Heart Study44
Mean
12.8±13.1
days
Change in
perceived risk
L
Persell
(2013)28
RCT USA Patient Usual care Patients were mailed a
risk message
containing their
personal CVD risk
information and
encouraging them to
discuss risk-lowering
options with their
primary care physician
10-year
Framingham
risk score
9 and
18 months
LDL cholesterol,
BP, prescriptions
for lipid-lowering
or
antihypertensive
medication,
smoking
cessation and
number of
primary care
physician
contacts
M
Price (2011)29 RCT UK Patient Told their individual
fasting glucose
level, blood
pressure and LDL
cholesterol and
whether they were
elevated according
to current guidelines
A 10-year
cardiovascular risk
estimate for current risk
and ‘achievable risk’
calculated assuming
current targets for
systolic BP, LDL
cholesterol, HbA1c and
10 year UKPDS
V.3.0 risk of
cardiovascular
disease
1 month Physical activity,
10-year CVD risk,
weight, body fat
percentage, BP,
alcohol
consumption,
LDL,
triglycerides,
M-H
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Table 1 Continued
Author and
date
Study
design Country
Recipient
of risk
information Control group Intervention group
Risk score
provided
Duration
of follow
up
Outcomes
measured
Quality
assessment*
±brief lifestyle
advice intervention
smoking cessation were
met±brief lifestyle
advice intervention
fructosamine,
fasting glucose,
2 h glucose,
vitamin C,
cotinine, anxiety,
quality of life,
self-regulation,
worry about
future risk of
heart attack,
intention to
increase physical
activity and
prescribing
Qureshi
(2012)30
Before-
after
study
UK Patient NA Cardiovascular risk
assessment then risk
score along with
lifestyle advice leaflet
posted within 4 weeks.
Participants with risk
>20% offered
appointment with their
family physician or
nurse 2 weeks later
10-year JBS2
cardiovascular
risk score
6 months Anxiety score,
self-reported fat
and unsaturated
fat intake,
smoking status
and stage of
change for
increasing
exercise
M
Bucher
(2010)31
RCT Switzerland Physician Physicians received
booklet of
evidence-based
guidelines for the
management of
CHD risk factors
and were advised in
the booklet to
access a website
for CHD risk
assessment
Physicians received
same booklet of
evidence-based
guidelines plus a risk
profile for each patient
on the patient charts
10-year
Framingham
risk
12–
18 months
Change in total
cholesterol, blood
pressure,
Framingham risk
score and
initiation of
medication
H
Hall (2003)32 RCT Scotland Physician Usual care—
physicians were
unaware of ongoing
study
Documentation of New
Zealand Cardiovascular
score at the front of
medical records
5-year
cardiovascular
risk from New
Zealand
Not given Change in
prescribing for
diabetes,
hypertension or
M
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Table 1 Continued
Author and
date
Study
design Country
Recipient
of risk
information Control group Intervention group
Risk score
provided
Duration
of follow
up
Outcomes
measured
Quality
assessment*
Cardiovascular
score45
lipid-lowering
drugs
Hanon
(2000)33
RCT France Physician Baseline
measurement of BP
and prescription of
fosinopril followed
by visits at 4 and
8 weeks at which
physicians could
add in
hydrochlorothiazide
As for control group
plus calculation of
Framingham risk also
given to physicians
10 year
Framingham
risk
8 weeks Change in blood
pressure, number
of patients with
dual
antihypertensive
therapy and
change in
Framingham risk
M
Grover
(2007)34
RCT Canada Physician
and patient
Physicians attended
full-day educational
session. Patients
received usual care
with follow-up at 2–
4 weeks and 3,6,9
and 12 months
Physicians attended the
same full-day
educational session.
Patients were given a
copy of their risk profile
and then followed up at
2–4 weeks, 3,6,9 and
12 months
10-year
Framingham
risk
12 months Change in
10-year risk of
CVD and
probability of
reaching lipid
targets
M-H
Grover
(2009)35
RCT Canada Physician
and patient
Physicians attended
full-day educational
session. Patients
received usual care
with follow-up at 2–
4 weeks and 3,6,9
and 12 months
Physicians attended the
same full-day
educational session.
Patients were given a
copy of their risk profile
and then followed up at
2–4 weeks, 3,6,9 and
12 months
10-year
Framingham
risk
12 months Mean blood
pressure
threshold for
intensifying
antihypertensive
treatment
M
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provision of risk information to different groups ranged
from a relative reduction of 10.6% to a relative increase
of 47.4% in ﬁbre intake. Only one study used an object-
ive measure of changes in diet (plasma vitamin C) and
also showed no signiﬁcant effect of risk information
among those with CVD risk >20% (standardised differ-
ence in means −0.079 (−0.37 to 0.21), p=0.589) at
1 month.29
Smoking cessation
Four studies reported on smoking cessation.25 29 30 36 All
showed no signiﬁcant effect of risk communication irre-
spective of differences in study design (before-and-after
study or RCT), duration of follow-up (1 to 12 months)
or outcome measure (self-report or objectively measured
cotinine): one found no signiﬁcant difference in the
percentage of smokers at 3 months with the mean differ-
ence adjusted for baseline and patients nested within
the same physician (−0.8%, p=0.64, control n=89, inter-
vention n=202);36 another measured smoking status
among participants with CVD risk >20% using cotinine
and also found no signiﬁcant difference (standardised
difference in means −0.53 (−1.23 to 0.17), p=0.136) at
1 month;29 the third, a before-and-after study, showed a
small but non-signiﬁcant increase in smoking (10.0% to
11.4% prerisk and postrisk information);30 and the
fourth showed mixed results with more factory workers
stopping smoking at 5 months in the group receiving
risk information and health education than health edu-
cation alone (9.6% vs 6.0%) but less stopping smoking
in the group receiving risk information and feedback on
cholesterol and health education than those receiving
feedback on cholesterol and health education alone
(3.6% vs 8.2%).25
Physical activity
Two studies reported on intention to increase physical
activity. Both showed no effect with one before-and-after
study including 11.4% of participants with CVD risk
>20% showing no change in the number of participants
in the action or maintenance stages of change for exer-
cise (n=145/298 prerisk information and n=151/298
postrisk information)30 and the other RCT showing no
signiﬁcant between-group differences in intention to
increase physical activity (no data given).29 Only one
study assessed change in physical activity and reported
no signiﬁcant difference in mean accelerometer counts
at 1 month among participants with CVD risk >20%
(standardised difference in means 0.086 (−0.20 to 0.37),
p=0.559).29
Alcohol consumption
Two RCTs showed no difference in self-reported alcohol
consumption. One including only participants with CVD
risk >20% reported no difference in mean alcohol
intake at 1 month (standardised difference in means=
−0.033 (−0.36 to 0.29), p=0.84)29 and the other no
change in the proportion of factory workers who
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Table 2 Quality assessment based on the Critical Appraisal Skills Programme guidelines
Author and
date
Addressed
a clearly
focused
issue
Appropriate
method
Recruitment
and
comparability
of study
groups Blinding
Exposure
measurement
Outcome
measurement Follow-up
Confounding
factors Analysis Results Overall
Asimakopoulou
(2008)20
• • • • • • • • • • L
Avis (1989)21 • • • • • • • _ • • L
Christensen
(1995)22
• • • _ • • • • • • L
Christensen
(2004)23
• • • • • • • _ • • L-M
Connelly
(1998)24
• • • • • • • • • • M-H
Hanlon (1995)25 • • • • • • • _ • • M
Hussein
(2008)26
• • • _ • • • • • • M
Paterson
(2002)27
• • • _ _ • • • • • L
Persell (2013)28 • • • • • • • _ • • M
Price (2011)29 • • • • • • • _ • • M-H
Qureshi (2012)30 • • • • • • • • • • M
Bucher (2010)31 • • • • • • • _ • • H
Hall (2003)32 • • • • • • • • • M
Hanon (2000)33 • • • • • • • _ • • M
Grover (2007)34 • • • • • • • _ • • M-H
Grover (2009)35 • • • • • • • _ • • M
Lowensteyn
(1998)36
• • • • • • • _ • • M
L, low; M, medium; H, high.
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Table 3 Details of participants
Author and
date
Study
design Inclusion criteria
Method of recruitment/
randomisation
n (% of those
eligible) Age (years)
Gender
(male)
Baseline CVD
risk score
Asimakopoulou
(2008)20
Before-after
study
Patients with type 2
diabetes free from
cardiovascular,
cerebrovascular or
psychiatric comorbidity and
able to understand English
Inspection of medical records
then letter of invitation and
randomisation to 1,5 or
10-year risk
95 (66%) Mean 64 (range
42–72)
44% Mean CHD
25% Mean
stroke 15%
Avis (1989)21 RCT Adults 25–65 years with no
history of CHD, diabetes or
hypertension
Random digit dialling then
randomisation to one of 4 risk
appraisal tools
Control: 89
Intervention: 542
NA NA Above
average risk
(risk ratio over
1.25): 36%
Christensen
(1995)22
Before-after
study
40–49-year-old men Randomly selected from
Public Health Insurance
register then invited by GP
Low / moderate risk:
150 (81%) High risk
123 (73%)
40–49 100% NA
Christensen
(2004)23
RCT 30–49 years old registered
with local GP
Letter of invitation to random
sample of those registered
with local practice then
randomisation into control and
2 intervention groups
(combined for analysis)
Control: 501 (75%)
Intervention: 905
(68%)
NA NA High risk
(score>10):
11.4%
Connelly
(1998)24
Before-after
study
Men aged 45–69 years
with no obvious
contraindications to
antithrombotic therapy, no
history of peptic ulceration
or previous history of MI,
stroke or serious
psychiatric disorder
Search of medication records
then letters of invitation
Baseline: 5772
(99%)
10 days: 4917 (85%)
3 months: 4244
(74%)
45–69 100% High risk
(highest
quintile):
18.4%
Hanlon (1995)25 RCT Workers at two work sites
not working permanent
night shifts, taking part in
another coronary
intervention or taking
lipid-lowering medication
Random selection of workers
then computer-generated
randomisation
Control: 229 (78%)
(HE only) and 226
(76%) (HE and
feedback on
cholesterol)
Intervention: 214
(75%) (HE and risk)
and 199 (76%) (HE,
feedback on
cholesterol and risk)
Control: 20–65
Intervention:
20–65
NA NA
Hussein
(2008)26
Before-after
study
People with complete data
available and no history of
CVD events
Self-selection at 2 events of
free stroke risk screening as
part of a community health
fair
146 (80%) Mean 47±15 36% High risk
(5%): 23.97%
Continued
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Table 3 Continued
Author and
date
Study
design Inclusion criteria
Method of recruitment/
randomisation
n (% of those
eligible) Age (years)
Gender
(male)
Baseline CVD
risk score
Paterson
(2002)27
Before-after
study
Age 30–74 years with
measurements for blood
pressure, smoking status,
total and high-density
lipoprotein cholesterol and
free from cardiovascular
disease
First 20 physicians who
responded to letter of
invitation. Physicians then
enrolled 2 patients who met
the study criteria and for
whom they would be likely to
use Heartcheck under normal
practice conditions
37 (92.5%) 50±10.7 68% Mean (SD):
10.8% (6.9)
Persell (2013)28 RCT Primary care physicians at
an academic medical
centre and patients aged
40–79 years without history
of CVD, DM or PAD, not
taking lipid-lowering
medication who had 2 or
more clinic visits in the
preceding 2 years and LDL
cholesterol test in previous
5 years with most recent
LDL ≥100 mg/dL and
10-year FRS >20% or LDL
≥130 mg/dL and FRS 10–
20% or LDL ≥160 mg/dL
and FRS 5–10%
Medical record search then
block randomisation at the
level of the practice using
random number generator
Control: 217
Intervention: 218
(93.6% across both
control and
intervention groups)
Control: 60.1±9.2
Intervention: 61.3
±9.4
Control: 77%
Intervention:
77.5%
Mean (SD):
14% (6.5)
Price (2011)29 RCT Patients with CVD risk
≥20%, able to read and
write English, not known to
have CVD or a physical
disability or other condition
reducing the ability to walk
Eligible patients mailed written
invitation and then factorial
computerised randomisation
Control: 91
Intervention: 94 (16%
across both control
and intervention
groups)
Control: median
(IQR) 62.4
(56.0–65.9);
Intervention:
median (IQR)
62.3 (54.2–66.2)
Control: 71%
Intervention:
64%
Median (IQR)
men: 48%
(34–60);
women 31%
(22–43)
Qureshi
(2012)30
Before-after
study
Aged 30–65 years
requesting a CVD risk
assessment by their family
physician without previous
diagnosis of diabetes or
CHD, stroke or PAD and
not already receiving
lipid-lowering medications
or excluded by their
physicians for
Usual practice Control: 353 (92.9%)
Intervention: 305
(80.3%)
Median 52 (45–
58)
39% High risk
(>20%):
11.4%
Continued
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Table 3 Continued
Author and
date
Study
design Inclusion criteria
Method of recruitment/
randomisation
n (% of those
eligible) Age (years)
Gender
(male)
Baseline CVD
risk score
psychological or social
reasons
Bucher (2010)31 RCT Patients registered at the
centres, not pregnant,
aged 18 or older with
continuous cART for
90 days prior to baseline
and with complete data on
CHD risk factors at
baseline
Physicians randomised in
strata according to patient
volume and type of setting
Control physicians:
57 (71%) Control
patients: 1682 (84%)
Intervention
physicians: 60 (71%)
Intervention patients:
1634 (78%)
Control: median
44 (39–50)
Intervention:
median 44
(39–51)
Control: 64%
Intervention:
68%
High risk
(>20%): 3%
Hall (2003)32 (R)CT Patients 35–75 years with
type 2 diabetes and no
history of CVD or renal
disease attending a
hospital outpatient clinic
Consecutive recruitment of
patients with alternate
allocation to experimental and
control group with doctors
unaware of project
Control: 161
Intervention: 162
NA NA High risk
(>20%): 52%
Hanon (2000)33 RCT Adults 18–75 years with
BP >140/90 without severe
hypertension, secondary
hypertension, heart
disease, CVD, renal,
pulmonary, hepatic disease
or significant psychiatric or
other serious illness,
diabetes, pregnancy or of
reproductive age without
effective contraception
Recruited during usual care
then randomised into 2
groups whether primary care
physician had been told CVD
risk
Control: 712
Intervention: 556
Control: Mean 60
±10 Intervention:
Mean 60±10
Control: 54%
Intervention:
54%
Mean (SD):
25.4% (12.0)
Grover (2007)34 RCT Patients with diabetes or
10-year risk > 30% with
moderate cholesterol,
10-year risk 20–30% with
high cholesterol or 10-year
risk 10–20% with very high
cholesterol with no
hypersensitivity to statins,
risk of pregnancy,
breastfeeding, active liver
disease, raised CK or
triglycerides, a history of
pancreatitis or significant
renal insufficiency*
Identified from office medical
records or prebooked clinic
appointments then
randomisation stratified by risk
level
Control: 1193
Intervention: 1163
(initial 98%
recruitment)
NA NA Mean (SD):
17.8% (7.5)
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decreased alcohol consumption after 5 months among
those drinking more than 21 units for men and 14 units
for women at baseline (p=0.064).25
Changes in intermediate measures
Cholesterol
Four RCTs reported the between-group difference in
mean change in total cholesterol or low-density lipopro-
tein cholesterol (LDL). Two were cluster randomised
studies in which physicians in the intervention group
received risk information about their patients.31 36 After
adjusting for lipid-lowering or antihypertensive medica-
tion at baseline31 and baseline characteristics and
patients nested within the same physician,36 neither
showed a difference in cholesterol after 3 months
(ﬁgure 2).
In the two other trials, risk information was given to
participants. In one, factory workers were randomised to
receive either health education±risk information or
health education and feedback on cholesterol±risk infor-
mation. There was no signiﬁcant difference in mean
change in plasma cholesterol at 5 months (pooled
difference in mean change −0.05 mmol/L (−0.13 to
0.03, p=0.208)) or 12 months (pooled difference in
mean change −0.025 mmol/L (−0.103 to 0.025,
p=0.529)).25 The other trial was the only one to include
participants with CVD risk >20% and showed a signiﬁ-
cant difference in mean change in LDL after 1 month29
with sensitivity analysis excluding participants who had a
change in drug treatment also showing a net 7.8% reduc-
tion in LDL (p<0.001).29 Combining the data for
5 months from Hanlon et al with Price et al gave a non-
signiﬁcant decrease, and pooling both with the other
two studies showed a trend towards lower cholesterol but
this was not signiﬁcant (p=0.069, I2=69.9%; ﬁgure 2).
No signiﬁcant differences were found with high-
density lipoprotein cholesterol (HDL) or total choles-
terol to HDL ratio after adjusting for baseline risk,36 or
with triglycerides29 or the number of patients who had
had their LDL repeated and in whom it was 30 mg/dL
or lower than baseline at 9 months (OR 0.99 (0.56 to
1.74))28 among those with CVD risk >20% or with raised
LDL. One RCT of participants with untreated hyperlip-
idaemia did, however, ﬁnd that patients were more likely
to reach lipid targets if they received risk information
(OR 1.26 (1.04 to 1.53), n=1163 (intervention) and
1193 (control)) and there was a signiﬁcant interaction
(p=0.04) between being given a risk proﬁle and the age
gap (estimated cardiovascular risk age minus actual age)
with the OR for reaching lipid targets in individuals who
were reassured that they were at low risk 0.92 (0.64 to
1.31) compared with 1.69 (1.21 to 2.36) for those in the
highest age gap quintile.34
Blood pressure
Five RCTs reported the difference in mean change in
blood pressure between patients with and without risk
information.28 29 31 33 36 Three provided risk
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information to physicians.31 33 36 All three showed a non-
signiﬁcant difference in mean change in systolic blood
pressure (SBP) or diastolic blood pressure (DBP).
Pooling the data from Bucher et al31 which is adjusted
for lipid-lowering medication or antihypertensive medi-
cation and Lowensteyn et al36 adjusted for group differ-
ences at baseline and patients nested within the same
physician gave a non-signiﬁcant reduction in both SBP
and DBP (ﬁgure 3A,B). It was not possible to pool the
data from Hanon et al33 because they reported only the
pooled blood pressure preintervention and postinterven-
tion (intervention group (n=556); preintervention SBP
167, SD 13; and postintervention SBP 140, SD 11; and
control group (n=712) SBP 166, SD 12, and 140, SD 10
preintervention and postintervention, respectively).
In the two other trials, risk information was provided
to patients.28 29 Both included only participants with
CVD risk >20% or raised LDL, and together they
showed a signiﬁcant reduction in SBP in those patients
that received risk information after 1 and 9 months
(ﬁgure 3A). Persell et al28 additionally showed no signiﬁ-
cant effect on DBP (ﬁgure 3B), and combining all ﬁve
studies together gave non-signiﬁcant differences in both
SBP and DBP (ﬁgure 3A, B).
Weight/BMI
Two studies reported changes in weight and found no
signiﬁcant difference in mean weight (standardised dif-
ference in means 0.065 (−0.22 to 0.35), p=0.66) or body
fat percentage (standardised difference in means 0.063
(−0.23 to 0.35), p=0.67) among participants with CVD
risk >20% at 1 month29 or mean change in body mass
index (BMI) at 3 months adjusted for baseline and
Figure 2 Forest plot showing
the effect of provision of
cardiovascular disease risk
estimates to physicians or
patients on the mean total
cholesterol or low-density
lipoprotein (LDL).
Figure 3 Forest plots showing the effect of provision of cardiovascular disease risk estimates to physicians or patients on the
mean change in (A) systolic blood pressure (SBP) and (B) diastolic blood pressure (DBP).
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patients nested within the same physician (mean differ-
ence 0.154, p=0.31).36
Glycaemia
Price et al29 reported no signiﬁcant change in fructosa-
mine (standardised difference in means 0.207 (−0.08–
0.50), p=−0.159), fasting glucose (standardised differ-
ence in means −0.024 (−0.31 to 0.26), p=0.87) or 2 h
glucose (standardised difference in means −0.022
(−0.31 to 0.27), p=0.88) among participants with CVD
risk >20% at 1 month.
Changes in modelled cardiovascular risk
Five RCTs reported changes in modelled CVD risk. In
three, risk information was provided to physicians.31 34 36
Bucher et al31 reported difference in mean change in
10-year Framingham risk after 12–18 months in
HIV patients after adjusting for lipid-lowering or anti-
hypertensive medication; Lowensteyn et al36 reported
the difference in mean change in 8-year coronary risk
after 3–6 months adjusting for baseline and patients
nested within the same physician; and Grover et al34
reported the difference in mean change in 10-year risk
of CVD after 12 months adjusted for baseline. Together,
they showed a statistically signiﬁcant reduction in mod-
elled risk (ﬁgure 4).
In the other two RCTs, risk information was provided
to patients.25 29 One found no signiﬁcant difference in
modelled risk at 1 month among those with CVD risk
>20% (standardised difference in change in means
−0.155±0.146, p=0.239).29 The other showed a non-
signiﬁcant increase at 5 months (difference in mean
change −0.154 (−0.373 to 0.066), p=0.171 on a scale
1–100 where 1 is highest risk) and non-signiﬁcant
decrease at 12 months (difference in mean change
0.167 (−0.116 to 0.450), p=0.248) among factory
workers.25 Combining the data from Hanlon et al at
12 months with the three studies providing risk informa-
tion to physicians gave a signiﬁcant reduction in risk
score (ﬁgure 4).
Changes in prescribing
Lipid-lowering medication
Four RCTs reported changes in lipid-lowering medica-
tion. One in which risk scores were provided to physi-
cians blinded to the trial showed a 42% increase in the
probability of having a change in lipid-lowering medica-
tion among all patients, but this was not statistically sig-
niﬁcant (p=0.29). In the same study, patients with a CVD
risk >20% were twice as likely to have their medication
changed when physicians were presented with the risk
score (relative risk (RR) 2.32 (1.01 to 5.29), p=0.03).32
The other three trials reported the difference in the
number of new prescriptions for lipid-lowering medica-
tion. Two gave risk information to physicians treating
patients with HIV,31 or patients with CVD risk >20% or
raised LDL,28 and one to patients with a CVD risk
>20%.29 When pooled there was RR of 1.35 not achiev-
ing statistical signiﬁcance (p=0.08, I2=0%; ﬁgure 5), but
when only those studies including participants with CVD
risk >20% or raised LDL are pooled, there is a signiﬁcant
increase in initiation of lipid medication (RR 1.83 (1.13
to 2.98)) which increases to 2.11 (1.27 to 3.49) when
only the two studies providing risk information to physi-
cians are included.
Blood pressure-lowering medication
Three RCTs reported changes in blood pressure-lowering
medication. As with lipid-lowering medication, Hall
et al32 showed no difference in the probability of a
change in medication among all patients (RR 1.52 (0.86
to 2.69), p=0.146) but patients with a CVD risk >20%
who received risk information were twice as likely to have
their medication changed (RR 2.38 (1.11 to 5.10),
Figure 4 Forest plot showing the effect of provision of
cardiovascular disease (CVD) risk estimates to physicians or
patients on the mean change in modelled CVD risk.
Figure 5 Forest plot showing the effect of provision of
cardiovascular disease risk estimates to physicians or patients
on the relative risk (RR) of receiving a change in lipid
medication.
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p=0.0189). The other two included only participants with
uncontrolled hypertension or CVD >20% or raised LDL
and reported no difference in the percentage of patients
requiring dual therapy after 8 weeks (46%, n=712 control
vs 41%, n=556 risk information),33 the percentage of
patients with uncontrolled hypertension at baseline who
had an increase in number of antihypertensive drug
classes (OR 2.89 (0.70 to 11.9) p=0.14)28 or the median
number of antihypertensive drug classes used (p=0.45).28
One study including only participants whose blood
pressure was above currently recommended targets
reported the mean blood pressure threshold for intensi-
fying treatment.35 They found no signiﬁcant difference
in the mean blood pressure thresholds for the whole
study population (difference in means 2.8 mm Hg (−0.5
to 6.0) for systolic BP and 1.1 mm Hg (−0.9 to 3.2) for
diastolic BP) or when stratiﬁed by age gap (the differ-
ence between their CVD risk age and chronological age).
Glucose-lowering medication
Three RCTs found no effect of risk information on
either change in medication in all participants (RR 1.17
(0.89 to 1.53), p=0.273) or those with CVD risk >20%
(RR 1.26 (0.87 to 1.84), p=0.219),32 or initiation of
medication following provision of risk information to
physicians caring for patients with HIV (RR 1.33 (0.30 to
5.96), p=0.704)31 or patients with CVD risk >20% (RR
6.78 (0.36 to 129.43)).29
Psychological well-being and anxiety
Psychological well-being following receipt of risk infor-
mation was assessed in four studies. Three showed no
difference. In the ﬁrst, a before-after study, there was no
signiﬁcant difference in the 12-item General Health
Questionnaire (GHQ) score after 6 months in either
those at low/moderate risk or those at high risk and no
signiﬁcant difference between the groups (n=146 in
low/moderate group and 116 in high-risk group,
p=0.80).22 A subsequent RCT also showed no signiﬁcant
difference in GHQ-12 after 1 year (p=0.603) or 5 years
(p=0.727) between those receiving risk information
(n=802, 745) and controls (n=390, 381).23 The third,
also an RCT,29 measured change in general health after
1 month using the EQ-5D-3L and showed no
between-group differences between those who received
the risk estimate only (mean change 0.05, SD 0.12) and
those who did not (mean change 0.01, SD 0.08; p=0.06).
A similar pattern of results was seen when the compari-
son was made between those who received risk estimate
+ lifestyle advice (mean change −0.003, SD 0.08) and
those who received lifestyle advice only (mean change
0.02, SD 0.11; p=0.442). The fourth used the GHQ-28
and showed a signiﬁcant (p<0.005) reduction in mean
scores from 7.21, SD 5.18 to 6.59, SD 5.7 in high-risk par-
ticipants after 10 days.24
Three studies also explored changes in anxiety. Two
were before-and-after studies and used the Spielberger
state anxiety inventory. As with psychological well-being
in the same study, a signiﬁcant reduction in mean
anxiety from 32.3, SD 8.72 to 28.1, SD 8.60 was seen in
high-risk participants after 10 days (p<0.005, n=1676),24
but this was not seen in the other study including all
participants after 6 months (median (IQR) prerisk 35
(26.7 to 43.3) and postrisk 33 (23.3 to 43.3)).30 The
third, an RCT, reported no signiﬁcant between-group
difference in change of anxiety at 1 month measured by
the six-item Spielberger state anxiety inventory when the
comparison was made between those who received risk
estimate only (mean change −0.45, SD 2.87) and
control group (mean change −0.63, SD 2.61; p=0.707).
A similar pattern of results was seen when the compari-
son was made between those who received risk estimate
+lifestyle advice (mean change −0.27, SD 2.87) and
those who received lifestyle advice only (mean change
−0.64, SD 3.21; p=0.324). The same study also found no
difference in worry about future risk of heart attacks,
measured using the adapted Lerman breast cancer
worry scale, or in self-regulation.29
Contact with healthcare professionals
Two studies reported the effect on healthcare usage of
giving risk information. In one,36 the design of the study
encouraged control patients to see their physician in
order to receive their risk score, and so follow-up was
higher in the control group. There was, however, a sig-
niﬁcant difference between low-risk and high-risk indivi-
duals (p for interaction 0.026) with high-risk individuals
being more likely to be followed up than low-risk
individuals.
A further study in the USA including only participants
with CVD risk >20% or with raised LDL showed no sig-
niﬁcant difference in healthcare usage at 9 months
between those receiving risk information (n=218) and
controls (n=217) with no difference in the percentage
with any follow-up visit (p=0.28), number of follow-up
visits (p=0.14), number of telephone (p=0.75) or email
(p=0.96) contacts.28
DISCUSSION
Principal findings
To our knowledge, this is the ﬁrst systematic review to
address speciﬁcally whether the provision of CVD risk
model estimates alone impacts patient or practitioner
behaviour or health outcomes. Despite the widespread
adoption of risk scores in guidelines,10–14 only 17 studies
were identiﬁed and they are heterogeneous in terms of
size, design, baseline level of risk and choice of out-
comes. They do, however, show that providing patients
with risk information changes risk perception and
increases the accuracy of perceived risk without decreas-
ing quality of life or increasing anxiety. While there is no
current evidence that this translates into changes in life-
style, small reductions in cholesterol, blood pressure and
modelled CVD risk are seen consistently. These may be
mediated through changes in prescribing: providing risk
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information to physicians leads to statistically signiﬁcant
changes in prescribing of both lipid-lowering and blood
pressure medications, with these effects greater in those
at higher risk. However, trends towards small reductions
in cholesterol and blood pressure were also seen in
studies in which risk information was only provided to
patients. Only one study included in our systematic
review was judged as high quality and most of the
studies relied on self-reported measures of health-related
behaviour. Consequently, there is a need for further
research with adequately powered trials and objective
outcomes to better understand the impact on behaviour
of provision of a CVD risk estimate to physicians and
individuals.
Strengths and weaknesses
The main strengths of this review are the use of broad
inclusion criteria and the systematic search of multiple
databases in addition to the inclusion of studies identi-
ﬁed in previous systematic reviews on related topics.
This allowed us to include studies in which assessment
of the impact of provision of a risk score alone was
not the primary outcome. While this reduces publica-
tion bias, the literature on CVD risk is diverse and
rapidly expanding, and so it remains possible that
there are additional studies of relevance that we were
not able to identify. Furthermore, additional studies
may have been published since June 2013, the date
of the literature search. We are not aware, however, of
any papers that would alter the overall conclusions
of this review.
The other main limitation, as with most systematic
reviews, is the extent and quality of the published data.
Given the interest in CVD prevention and widespread
use of CVD risk scores, it is both surprising and con-
cerning that so few studies concerning their impact on
care have been published. Additionally, of the 17 studies
identiﬁed, most report only short-term changes
(<6 months) and those that address behaviour change
use mostly self-reported measures and are underpow-
ered to detect small changes that may be clinically
important at the population level. The small number
and heterogeneity of the studies also made combining
results difﬁcult. Not only did they report different out-
comes at different time periods with participants of
varying baseline risk, but many of the studies adjusted
for different baseline variables without reporting
unadjusted changes or provided insufﬁcient data to
allow us to calculate effects adjusted for baseline risk.
Data on the SD of outcomes were also not available for
most studies, meaning it was not possible to calculate
standardised changes in outcomes. A further limitation
was that the small number of studies differed in
whether the risk model estimates were presented to
patients or physicians. This meant that in most cases
there were only one or two studies presenting risk
model estimates to the same group and reporting the
same outcome. To provide the greatest interpretation of
this limited data, where we were able to synthesise the
data, in addition to presenting these separately, we also
presented an overall summary estimate. Although this
means these estimates need to be interpreted with
caution, they probably reﬂect real life as in routine clin-
ical practice this distinction is often not as clear cut:
physicians will often discuss risk estimates with patients
and patients will often ask physicians for advice on inter-
preting estimates.
Implications for clinicians and policymakers
Despite these limitations, the results from this review are
of relevance to the large number of clinicians worldwide
who use CVD risk information with patients regularly in
their practice, and policymakers involved in designing
and implementing strategies for the prevention of CVD,
including the recent debate about the NHS programme
of CVD risk reduction in the UK.
The ﬁnding that providing patients with risk informa-
tion changes risk perception and increases the accuracy
of perceived risk is consistent with previous reviews
which have shown that global risk information with
accompanying education or counselling increases the
accuracy of perceived risk.17 However, even immediately
after being provided with risk information, 1 in 4 partici-
pants still had an inaccurate perceived risk26 and 1 in 10
changed their perceived risk in the opposite direction to
the feedback they received.21 Such challenges to the
communication of risk are well known,46 and there is
scope for further work, but this highlights the need for
clinicians to remain aware of the limitations of current
methods.
With this inaccuracy in risk perception along with
existing experience from other areas about the chal-
lenges of behaviour change, it is perhaps not surprising
that there is no evidence that simply providing patients
with a number leads to statistically signiﬁcant changes in
habitual environmentally cued behaviours such as diet,
smoking, physical activity or alcohol intake. Where there
were differences between the groups, most were in
favour of providing risk information but the studies were
generally of poor quality, underpowered and imprecise
with most relying on self-reported information. While we
are, therefore, unable to rule out the possibility of a
small potentially clinically important effect, we can say
that it appears unlikely that providing risk information
will result in harm through false reassurance and the
adoption of unhealthy behaviours. There was also either
no change or an improvement in psychological well-
being, anxiety, worry about future risk of heart attacks,
or self-regulation in these studies. This is an important
ﬁnding as screening programmes based on risk assess-
ment such as the NHS Health Checks in the UK have
the potential to cause harm and a key decision when
considering implementation is the extent of that harm.
Our review suggests that such screening programmes are
safe when it comes to psychological well-being.
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The effect of the provision of risk information on
intermediate measures of CVD and modelled CVD risk
was more consistent with studies consistently showing
reductions in cholesterol, SBP and DBP, and modelled
CVD risk. While the effect sizes are small, they may be
of clinical signiﬁcance at the population level and those
studies including only high-risk participants showed sig-
niﬁcant reductions in cholesterol and SBP. It is possible
these effects are mediated through changes in prescrib-
ing: although only on the border of statistical signiﬁ-
cance, patients were 1.4–1.5 times more likely to have a
change of lipid-lowering or blood pressure medication
when risk information was provided to their physicians
and this increased to over twice as likely when only
those with a CVD risk >20% were included. This differ-
ence in prescribing is not unexpected. Guidelines for
prescribing lipid-lowering and blood pressure medica-
tion are based on assessment of CVD risk. The increased
prescribing for those at high risk therefore likely reﬂects
a greater number of physicians following existing guid-
ance and the smaller effect in those studies including
low-risk participants, the effect of including participants
in whom no change in treatment would be expected.
Trends towards small reductions in cholesterol and
blood pressure were also seen in studies in which risk
information was only provided to patients. This high-
lights the central role patients have in making decisions
about their treatment and the impact their risk percep-
tion and views about preventive medicine have on the
outcomes: while some may be risk averse and start medi-
cation at low-risk levels, we know from existing literature
that many patients are reluctant to start medication with
5% of people on the streets of London stating that they
would not take a statin even if it gave them another
5 years of life,47 and people responding to a US-based
internet survey prepared to pay an average of $1445
(£948; €1265) to avoid taking one pill a day for CVD
prevention.48 The impact of provision of risk informa-
tion is, therefore, complex and is likely to reﬂect a com-
bination of factors from initial risk perception, peer
comparison, beliefs about the disease, and to-date
unmeasured effects such as medication adherence.
Unanswered questions and future research
While this review shows that provision of risk informa-
tion to patients and physicians improves accuracy of risk
perception, increases prescribing and reduces levels of
CVD risk factors and modelled CVD risk without causing
changes in psychological well-being or anxiety, no
studies included actual CVD events as an outcome, and
so we are unable to comment on the effect of risk infor-
mation on CVD morbidity or mortality. Additionally,
while there is some suggestion that the effects may be
greater in those at higher risk, with such a small number
of studies that could simply reﬂect regression to the
mean. There is, therefore, a need for further research
with adequately powered trials with objective outcomes
and longer follow-up to understand how best to
communicate risk information to increase understand-
ing, enhance shared decision-making and encourage
behaviour change.
We are also unable to comment on the cost-
effectiveness of provision of risk information and
whether risk information delivered directly to patients is
comparable to physician-led risk assessment. In the
current age of increasing demand for healthcare and
rising costs of treatment, ways of stratifying the popula-
tion to enable delivery of interventions to those most
likely to beneﬁt are of increasing interest, but with such
small changes observed in these studies, the question
remains as to whether greater beneﬁt could be derived
from investment in population-wide prevention strat-
egies49 rather than screening and individual risk
assessment.
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